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GABA in the Endocrine Pancreas
 
 
 
-Aminobutyric acid (GABA) is a principal nonpeptidal
neurotransmitter with a well-characterized role as an
inhibitor of neuronal ﬁring in the CNS (Cherubini et
al., 1991; Thomas-Reetz and De Camilli, 1994). GABA
is also found in other tissues, such as the endocrine
pancreas (Thomas-Reetz and De Camilli, 1994). In the
neuron, GABA is synthesized in close proximity to syn-
aptic vesicles, it is produced from glutamate by the en-
zyme glutamate decarboxylase (GAD) and then trans-
ported into the synaptic vesicles against a proton elec-
trochemical gradient (Thomas-Reetz and De Camilli,
1994). Exocytosis of neuronal synaptic vesicles is trig-
gered when voltage-sensitive calcium channels open,
causing a transient increase in cytosolic calcium. GABA
is consequently released into the synaptic space, where
it interacts with ionotropic receptors on the postsynap-
tic membrane, increasing their chloride conductance
and thereby inducing membrane hyperpolarization
 
and inhibition of exocytosis (Cherubini et al., 1991;
Thomas-Reetz and De Camilli, 1994). However, when
the electrochemical chloride gradient across the mem-
brane is directed outward, as in neonatal hippocampal
neurons, GABA is excitatory (Cherubini et al., 1991).
The endocrine pancreas also contains high concen-
trations of GABA, and the 65-kD isoform of GAD (GAD
65) predominantly in the core of the islets of Langer-
hans, where insulin-producing 
 
 
 
-cells are located (So-
renson et al., 1991; Thomas-Reetz and De Camilli,
1994; Chessler et al., 2002). For more than three de-
cades the role of 
 
 
 
-cell GABA has puzzled scientists,
with interest intensifying on the discovery that GAD 65
is one of the major autoantigens in type 1 diabetes mel-
litus, a disease in which 
 
 
 
-cells are systematically de-
stroyed by an autoimmune mechanism (Yoon et al.,
1999). Evidence suggests that 
 
 
 
-cell GABA localizes to
synaptic-like microvesicles (SLMVs) and is exocytosed
in a regulated manner, as it is in neurons (Thomas-
Reetz and De Camilli, 1994). What are the stimuli for
 
 
 
-cell GABA release? Which islet cell type/s are the tar-
gets of this fast-acting signaling molecule and what, if
any, are its effects on hormone secretion? These im-
portant questions have remained unanswered largely
because of the difﬁculty in obtaining quantitative
amounts of secreted GABA to detect temporal changes
in GABA release. A fresh approach to the detection of
secreted GABA, providing both high temporal resolu-
tion and sensitivity, is presented by Braun and col-
leagues in this issue (Braun et al., 2004). This new
methodology and its application contribute a signiﬁ-
cant step toward the characterization of the mecha-
nisms of 
 
 
 
-cell GABA release and offers a platform for
further studies of GABA stimulus-secretion coupling
and SLMV exocytosis.
 
SLMVs in 
 
 
 
-cells
 
SLMVs have been identiﬁed in peptide-secreting endo-
crine cells, including those in the gut, adrenal chroma-
fﬁn cells, and the pancreatic islets (Thomas-Reetz and
De Camilli, 1994; Anhert-Hilger et al., 1996). These mi-
crovesicles are classiﬁed as synaptic-like because they
contain membrane proteins involved in neuronal syn-
aptic vesicle exocytosis, including synaptophysin, the
vSNARE (vesicular soluble 
 
N
 
-ethylmaleimide-sensitive
factor attachment receptor) synaptobrevin-2, and the
putative calcium sensor synaptotagmin I/II (Thomas-
Reetz and De Camilli, 1994; Regazzi et al., 1995; Lang
et al., 1997). Other proteins implicated in the regula-
tion of exocytosis, e.g., SNAP25, syntaxin I, and Rab3,
have been identiﬁed in 
 
 
 
-cells and derived cell lines
(Lang, 1999). Ultrastructural studies have previously
demonstrated that 
 
 
 
-cell SLMVs are distinct in both ap-
pearance and size from the insulin-containing large
dense core vesicles (LDCVs) (Sorenson et al., 1991;
Lang et al., 1997). Now, Braun et al. (2004), provide
quantitative information and show that a proportion of
these SLMVs appear to be localized in abundance at
the plasma membrane, with some vesicles apparently
docked (Braun et al., 2004). The striking similarity be-
tween 
 
 
 
-cell SLMVs and neuronal synaptic vesicle mor-
phology, subcellular distribution and the overlap in
exocytosis-associated membrane proteins suggests that
they may share a role as vehicles for storage and release
of signaling molecules. 
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GABA Is Synthesized in 
 
 
 
-cells
 
An extensive body of research has demonstrated that
GABA is present in high levels within pancreatic islets,
and that the majority is localized to the 
 
 
 
-cells, al-
though small amounts are also detected in the islet
mantle (for review see Sorenson et al., 1991; Gilon et
al., 1991). GABA is synthesized in the cytosol from its
precursor glutamate by GAD. Glutamate is generated
in the mitochondria, either from the TCA-cycle inter-
mediate 
 
 
 
-ketoglutarate by glutamate dehydrogenase
or by other transamination reactions. Glutamate is
then transferred to the cytosol, where it can also be
produced by glutaminolysis. GABA catabolism occurs
in the mitochondria where GABA is transaminated with
 
 
 
-ketoglutarate by GABA transaminase to form succi-
nate semialdehyde. This has been referred to as the
GABA shunt (Sorenson et al., 1991). 
 
 
 
-cells express
high levels of GAD 65, the membrane-associated iso-
form of GAD, which is also linked with synaptic vesi-
cles in neurons (Thomas-Reetz and De Camilli, 1994;
Chessler et al., 2002). High levels of GAD activity have
indeed been detected in islets (Sorenson et al., 1991).
GAD 67, another isoform of GAD, exhibits different
subcellular localization to GAD 65 in 
 
 
 
-cells and neu-
rons (Thomas-Reetz and De Camilli, 1994). This iso-
form has been identiﬁed in rat but not in human or
mouse islets (Shi et al., 2000; Chessler et al., 2002). In
rat, GAD 67 appears to be more abundant in the islet
mantle, where glucagon-secreting 
 
 
 
-cells and soma-
tostatin-secreting 
 
 
 
-cells predominate, rather than in
the 
 
 
 
-cell containing core, where GAD 65 is exclusively
localized (Chessler et al., 2002). However, it should be
noted that endocrine cells might not be the only source
of islet GABA in vivo and in some experimental sys-
tems, such as isolated islets and in situ perfused pan-
creas. The presence of GABAergic neurons, closely as-
sociated with, and indeed penetrating into the islet
mantle, has been conﬁrmed by immunocytochemistry
(Sorenson et al., 1991).
 
Is 
 
 
 
-cell GABA Localized within SLMVs?
 
Although a direct demonstration of GABA localization
in 
 
 
 
-cell SLMVs by immunogold electron microscopy is
lacking, such analyses have thus far indicated that
GABA is concentrated in regions enriched with SLMVs
(Reetz et al., 1991) and indeed excluded from LDCVs
(Braun et al., 2004, this issue). Moreover, GAD 65
clearly colocalizes with 
 
 
 
-cell SLMV membrane pro-
teins, as it does with synaptic vesicles in neurons,
strongly supporting the notion that GABA is trans-
ported into SLMVs once synthesized (Reetz et al.,
1991). Uptake studies of radio-labeled GABA by puri-
ﬁed SLMVs of the 
 
 
 
-cell line 
 
 
 
TC3 have revealed an
ATP-dependent proton ionophore-sensitive GABA up-
 
take mechanism, similar to that observed in neuronal
synaptic vesicles (Thomas-Reetz and De Camilli, 1994).
A similar demonstration of ATP-dependent GABA up-
take was made in permeabilized RIN 38 cells, a pancre-
atic 
 
 
 
-cell line (Anhert-Hilger et al., 1996). The only ﬂy
in the ointment is that the GABA/glycine transporter
VGAT (VIAAT), initially characterized in GABAergic
neuronal cells (McIntire et al., 1997), was recently
identiﬁed in rat, but not human islets (Chessler et al.,
2002). Moreover, the VGAT expression pattern paral-
leled that of GAD 67, being more abundant in the islet
mantle than the core (Chessler et al., 2002). It is possi-
ble that 
 
 
 
-cells utilize an alternative transporter for
GABA uptake into SLMVs, which displays similar prop-
erties to the neuronal vesicular transporter. Despite the
lack of a molecular identity for the 
 
 
 
-cell vesicular
GABA transporter, it seems that GABA is in all probabil-
ity stored in, and exocytosed from, SLMVs, as has be-
come increasingly evident from studies of GABA secre-
tion, discussed below.
 
Regulated GABA Release from 
 
 
 
-cells
 
Synaptic vesicle exocytosis in neurons occurs by regu-
lated rather than constitutive exocytosis, in response to
a transient rise in cytosolic calcium (Thomas-Reetz and
De Camilli, 1994). Is 
 
 
 
-cell GABA also released by a reg-
ulated process? Studies of GABA release have until now
required large amounts of starting material, usually cell
lines, to obtain sufﬁcient amounts of secreted GABA
for quantitative analysis. These studies have revealed
that in the 
 
 
 
-cell line RIN 38, and the neuroendocrine
cell line BON, GABA secretion can be stimulated by
high concentrations of extracellular K
 
 
 
, or the calcium
ionophore A23187, both dependent on the presence of
extracellular calcium (von Blankenfeld et al., 1995; An-
hert-Hilger et al., 1996). GABA release from BON cells
was also stimulated twofold by the cAMP-raising agent
IBMX, a phosphodiesterase inhibitor (John et al.,
1998). This suggests that, like insulin secretion, GABA
is released in response to an increase in cytosolic cal-
cium, as a result of membrane depolarization, which
triggers the opening of voltage-gated calcium channels.
Other studies in MIN6 cells, a widely used mouse 
 
 
 
-cell
line, have shown that GABA release can be stimulated
up to threefold by mastoparan, a wasp venom peptide
that activates G-proteins and stimulates LDCV exocyto-
sis (Ohara-Imaizumi et al., 2001). Moreover, mastopa-
ran-stimulated GABA release was attenuated by the tet-
anus toxin C1 light chain, a neurotoxin that cleaves
synaptobrevin-2. In contrast, overexpression of the
t-SNARES SNAP 25 or syntaxin IA inhibited masto-
paran-induced insulin secretion but not GABA release
(Ohara-Imaizumi et al., 2001). These ﬁndings imply
that regulated GABA release involves similar but not
identical mechanisms to those of insulin secretion. 
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Both of these processes appear to involve machinery
implicated in neurotransmitter release.
The notion that 
 
 
 
-cell GABA release is a regulated
process has been reinforced by Braun et al. (2004) us-
ing dispersed rat islets. The authors employed an ade-
noviral system to overexpress the GABA
 
A
 
 receptor, a
GABA-activated Cl
 
 
 
 channel, as a novel detection sys-
tem for GABA release. To this end, whole-cell patch-
clamped 
 
 
 
-cells were used as biosensors for their own
secreted GABA, detected as ﬂuctuations in current
(current transients). The authors show that GABA re-
lease occurred in response to membrane depolariza-
tion, dependent on the entry of extracellular calcium
through Cd
 
2
 
 
 
-sensitive (voltage-gated) channels. The
release of caged calcium in GABA
 
A
 
 receptor overex-
pressing 
 
 
 
-cells also induced an increase in transient
currents associated with receptor activation. These
ﬁndings demonstrate that calcium entry through volt-
age-gated channels, and not membrane depolarization
itself, can trigger GABA release. Interestingly, when the
concentration of calcium within the pipette solution
was increased from 3–25 
 
 
 
M, a twofold increase in
GABA
 
A
 
-mediated current changes and a similar in-
crease in total membrane capacitance was observed. As
the authors state, an increase in cell capacitance is
largely reﬂective of exocytosis of LDCVs rather than
SLMVs (
 
 
 
2% of total increase). However, this does not
necessarily indicate that the same calcium sensor is in-
volved in GABA (SLMV) and LDCV release, as the sen-
sors identity and detailed calcium-dose response rela-
tionships remain to be established. It was also noted
that depolarization-induced current changes rapidly
desensitized, but recovered after a 2-min break in trains
of depolarizations. This supports a vesicular origin for
GABA, perhaps within readily releasable and reserve
SLMV pools, compatible with their ultrastructural ﬁnd-
ings. In agreement with the stimulatory effect of IBMX
on GABA release from neuroendocrine cell lines (John
et al., 1998), the presence of forskolin, an adenylate cy-
clase activator, increased the number of depolarization-
induced GABA release events detected (Braun et al.,
2004). Therefore, cAMP acts as a potentiator not only
of LDCV, but also SLMV exocytosis (Lang, 1999).
 
Does High Glucose Stimulate 
 
 
 
-cell GABA Release?
 
An important question when considering the role of
GABA as an intraislet paracrine signaling molecule
must be whether islet GABA secretion is stimulated, as
insulin, or inhibited during post-prandial hyperglyce-
mia. Glucose metabolism stimulates LDCV exocytosis
by depolarizing the plasma membrane, which pro-
motes calcium inﬂux through voltage-gated calcium
channels (Lang, 1999). Many authors who believe
GABA secretion is stimulated by glucose have relied on
an early paper demonstrating an increase in GABA re-
 
lease from the 
 
 
 
-cell line 
 
 
 
TC6 only apparent after a
long (total of 12 h) exposure to high glucose (Gaskins
et al., 1995). However, such a prolonged exposure to
high glucose may have altered the expression of the en-
zymes involved in GABA metabolism, or SNARES in-
volved in SMLV exocytosis. Moreover, a concurrent in-
crease in glucose-induced insulin secretion was not
demonstrated, questioning the validity of this cell line
as a model for primary 
 
 
 
-cells. In another paper where
the widely accepted 
 
 
 
-cell model, MIN6, was used, no
signiﬁcant increase in GABA release was observed after
a 2-h incubation in high glucose, contrasting with a
twofold stimulation of insulin secretion (Nagamatsu et
al., 1999), also reported in a later study (Hayashi et al.,
2003).
A mere handful of studies have addressed the ques-
tion of glucose-stimulated GABA secretion in primary
pancreatic preparations. Increased GABA release in
the presence of high glucose was detected using pieces
of rabbit pancreas (Gerber and Hare, 1980). After 15
min, a twofold increase in secreted GABA was ob-
served. However, a convincing demonstration of glu-
cose-induced insulin secretion was again lacking in this
study. In contrast, a later investigation showed inhibi-
tion (40%) of GABA release from reaggregated rat
 
 
 
-cells after a 2-h (or 24-h) culture period in high when
compared with low glucose conditions. A threefold in-
crease in insulin secretion was observed in parallel
(Winnock et al., 2001). In agreement with this ﬁnding,
a second study demonstrated a twofold increase in
GABA release from rat islets after 30 min when islets
were transferred from high to low glucose conditions
(Hayashi et al., 2003). A concurrent decrease in insulin
secretion was conﬁrmed.
The overall trend from these studies is not clear and
so the effect of glucose on GABA release remains in-
conclusive. However, the function of GABA in the CNS
as a fast-acting signaling molecule should be consid-
ered. All of the aforementioned studies examined
GABA release after a relatively long incubation time
(minutes to hours), which might be inappropriate for
analyzing physiologically relevant GABA secretion. The
new approach by Braun et al. (2004) enables GABA
exocytosis to be monitored in real-time over millisec-
onds to seconds. Although glucose-induced GABA se-
cretion was not demonstrated directly by Braun et al.
(2004) it was inferred by the ability of a depolarization-
induced calcium rise to elicit GABA secretion. Their
GABA biosensor approach could be used to directly
substantiate the effect of glucose by patch clamp moni-
toring of membrane currents in “sniffer” cells, overex-
pressing the GABA
 
A
 
 receptor, but located adjacent to
normal 
 
 
 
-cells. “Sniffer” cells would not be anticipated
to sense glucose as they would be patched in whole-cell
mode. Superfusion with high glucose could stimulate 
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GABA release from control cells, and in turn activate
the GABA
 
A
 
 receptors on the “sniffer” cells.
 
GABA Receptor Expression in the Endocrine Pancreas
 
There are two distinct types of GABA receptors in the
CNS, the ionotropic GABA
 
A
 
 (a chloride channel) and
GABA
 
C
 
 receptors, and the metabotropic GABA
 
B
 
 recep-
tor. GABA
 
B
 
 is a G-protein coupled receptor that can
suppress presynaptic neurotransmitter release. This in-
volves the direct inhibition of voltage-gated calcium
channels, or the reduction of postsynaptic neuron ﬁr-
ing by indirectly activating Kir3-type potassium channel
subunits and inhibiting adenylate cyclase via G-protein
subunits (Kaupmann et al., 1998). It is widely accepted
that GABA
 
A
 
 receptor is expressed in the islet. However,
exactly which islet cell types express this receptor is still
to be elucidated. In whole human islets, the 
 
 
 
2, 
 
 
 
3 and
 
 
 
1 subunits of the GABA
 
A
 
 receptor were detected by
RT-PCR, a more limited spectrum than in the brain
(
 
 
 
1–6, 
 
 
 
1–3, 
 
 
 
1–2), perhaps indicative of only one
pharmacologically distinct receptor or expression in
just one cell type (Yang et al., 1994). In the rat islet,
however, antibodies against 
 
 
 
1 and 2 and 
 
 
 
1 and 
 
 
 
2 all
strongly stained all cell types (von Blankenfeld et al.,
1995). Immunostaining of guinea pig pancreatic islets
indicated that GABA
 
A
 
 receptors are expressed in 
 
 
 
 and
 
 
 
, but not 
 
 
 
-cells (Rorsman et al., 1989). GABA
 
B
 
 recep-
tors have been detected by both RT-PCR and Western
blotting in whole human islets and MIN6 cells (Brice et
al., 2002). In view of the apparent discrepancies be-
tween species, detailed islet cell-type speciﬁc molecular
proﬁling of GABA receptors should be performed.
 
GABA Action on Islet Hormone Release
 
The existence of large amounts of GABA in 
 
 
 
-cells, the
likelihood that it is released from SLMVs in a regulated
manner, and the presence of GABA receptors on neigh-
boring islet cells strongly suggests a signaling role for
GABA within the microorgan. Does GABA act as a mod-
ulator of islet hormone release by auto and/or para-
crine actions? In vivo, insulin is secreted from 
 
 
 
-cells
and somatostatin from 
 
 
 
-cells during hyperglycaemia,
whereas 
 
 
 
-cells are active in the hypoglycaemic state.
The evidence presented below advocates that insulin se-
cretion may be inhibited by GABA. In the perfused rat
pancreas, where islet microcirculation is preserved, glu-
cose-induced insulin secretion was inhibited in a dose-
dependent manner by both GABA and baclofen (a
GABA
 
B
 
-speciﬁc agonist), indicative of GABA action by
the GABA
 
B
 
 receptor (Gu et al., 1993). The underlying
mechanism for this could be the attenuation of the glu-
cose-evoked increase in cytosolic calcium, as seen in iso-
lated 
 
 
 
-cells (Gu et al., 1993). In a separate study, musci-
mol (a GABA
 
A
 
 receptor agonist) had no effect on glu-
cose-induced insulin secretion in the perfused rat
pancreas, despite a concurrent inhibition of somatosta-
tin release (Robbins et al., 1981). These ﬁndings indi-
cate that GABA
 
A
 
 receptors may be expressed on delta
but not 
 
 
 
-cells, in agreement with receptor localization
studies in guinea pig islets discussed above (Rorsman et
al., 1989). Surprisingly, however, GABA had no effect
on arginine-stimulated somatostatin release from iso-
lated guinea pig islets (Rorsman et al., 1989). This dis-
crepancy between results from isolated islets and per-
fused pancreata has also been seen for insulin secre-
tion. In studies of rat islets, GABA, muscimol, or
baclofen had no effect on insulin or somatostatin re-
lease (Gilon et al., 1991). Such ﬁndings are consistent
with the concept that GABA may act as an autocrine in-
hibitor of insulin secretion, at least in rodents.
There is evidence to suggest that in some species
GABA can inhibit the secretion of the blood-glucose–
elevating hormone glucagon. In studies of isolated is-
lets, GABA has been shown to inhibit arginine-induced
glucagon release in guinea pig islets (Rorsman et al.,
1989) and glucagon release from mouse islets (Gilon et
al., 1991). In the latter experiment, the same result was
obtained with muscimol, but not bacolfen, indicative of
GABA action via the GABA
 
A
 
 receptor. Importantly,
muscimol was also found to inhibit arginine-induced
glucagon secretion in the perfused rat pancreas (Gilon
et al., 1991). In the 
 
 
 
TC6 cell-line, glucagon secretion
was inhibited by GABA in a dose-dependent manner, in
low (1 mM) but not in high (10 mM) glucose (Gaskins
et al., 1995). Under the latter condition, glucagon se-
cretion appeared to be already maximally inhibited.
These ﬁndings lead us to the interesting possibility that
GABA might act as a paracrine inhibitor of glucagon se-
cretion in high glucose conditions, as previously pro-
posed (Rorsman et al., 1989).
 
GABA as a Paracrine Regulator of Glucagon Secretion
 
In conditions where 
 
 
 
-cell insulin secretion is stimu-
lated by nutrients, glucagon release is suppressed. In
vivo, this situation occurs during hyperglycaemia, but is
known to be deranged in the diabetic state where insu-
lin secretion is impaired. The concept of paracrine reg-
ulation of glucagon secretion by secretory products
from 
 
 
 
-cell LDCVs, has recently been addressed (Ishi-
hara et al., 2003). Candidate paracrine inhibitors in-
clude insulin and zinc (Ishihara et al., 2003), the latter
cocrystallizes with insulin in LDCVs. To also qualify as a
paracrine inhibitor during hyperglycemia, GABA must
be released under high glucose conditions.
Given the ability of GABA to hyperpolarize the
plasma membrane of neuronal cells, a similar effect on
the 
 
 
 
-cell plasma membrane could be envisaged to
have an inhibitory effect on exocytosis of glucagon-con-
taining LDCVs. Indeed GABA hyperpolarization of the
plasma membrane and concurrent inhibition of spon- 
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taneous calcium spiking has been demonstrated with
the cell-attached patch clamp technique in isolated
guinea pig 
 
 
 
-cells (Rorsman et al., 1989). It is notewor-
thy that the fundamentals of voltage-gated calcium in-
ﬂux–dependent LDCV exocytosis are similar in 
 
 
 
- and
 
 
 
-cells (Ishihara et al., 2003). Indirect evidence for a
hyperpolarization effect of GABA on stimulated rat
 
 
 
-cells has been reported (Gu et al., 1993).
Evidence for paracrine suppression of glucagon se-
cretion by GABA during glucose stimulation remains
controversial. The GABA
 
A
 
 receptor antagonist bicu-
culline was unable to prevent high glucose-associated
inhibition of arginine-induced glucagon secretion in
the perfused rat pancreas (Gilon et al., 1991). This
ﬁnding is signiﬁcant in view of the preserved islet mi-
crocirculation in the perfused pancreas set-up (see be-
low). Only one study has demonstrated an antagonistic
effect of bicuculline (50%) on high glucose-associated
inhibition of glucagon secretion in the guinea pig islet
(Rorsman et al., 1989). However, the action of bicu-
culline on glucagon release in low glucose conditions
was not explored, and indeed a stimulatory effect of
bicuculline on somatostatin release from the same is-
lets exposed to low glucose and arginine was observed
(Rorsman et al., 1989). This raises the possibility that
interstitial GABA may have acted as an inhibitor of glu-
cagon secretion in both low and high glucose condi-
tions. It is clear, therefore, that the actions of GABA on
islet hormone release need to be elucidated.
 
Islet GABA and Glutamate as Paracrine Effectors
 
Evidence suggests that the LDCVs of 
 
 
 
-cells contain
glutamate. This is suggested by the colocalization of the
glutamate transporters VGLUT1 and VGLUT2 with glu-
cagon-positive secretory granules and L-glutamate (Ha-
yashi et al., 2003). Glutaminase, usually enriched in
glutaminergic nerve endings, was also detected in
 
 
 
-cells (Inagaki et al., 1995). L-glutamate is the major
excitatory neurotransmitter in the CNS, and like GABA,
is stored and released from synaptic vesicles. Activation
of ionotropic L-glutamate receptors has been shown to
stimulate insulin secretion from rat islets at permissive
glucose concentrations (Inagaki et al., 1995), whereas
GABA release was evoked at low glucose concentrations
(Hayashi et al., 2003). Glutamate is also present in
 
 
 
-cells, generated from glucose, and thought to partici-
pate as an intracellular cofactor in nutrient-stimulated
insulin secretion (Maechler and Wollheim, 1999). The
colocalization of glutamate with glucagon could suggest
that any intraislet glutamate paracrine signaling activity
occurs during hypoglycaemia, as supported by the ob-
servation that glutamate release from islets is greater in
low rather than high glucose conditions (Hayashi et al.,
2003). In contrast, the distinct partitioning of GABA
and insulin within the 
 
 
 
-cell to the SLMVs and LDCVs,
 
respectively, confers possibilities for tailored stimulatory
and inhibitory signaling pathways for exocytosis.
Paracrine signaling in the in situ islet is dictated by
the direction of the microcirculation. It is generally be-
lieved that the intraislet portal system places the 
 
 
 
 and
 
 
 
-cells, situated in the islet mantle, downstream of the
 
 
 
-cells in the core. This is supported by the observation
that glucagon secretion is suppressed when 
 
 -cells are
activated and  -cell hyperfunction in the absence of
 -cells (Ishihara et al., 2003). What roles can be envis-
aged for the two candidate signaling molecules GABA
and glutamate in the short-term regulation of islet hor-
mone secretion? Under conditions where both SLMV
and LDCV exocytosis is stimulated, GABA could act as
an autocrine inhibitor of insulin secretion. In this situa-
tion, GABA may well act as a paracrine inhibitor of glu-
cagon and somatostatin release (see Fig. 1). Glutamate,
however, is a conceptually less attractive paracrine regu-
lator of  -cell vesicular exocytosis in the light of our
current understanding of islet microcirculation. We an-
ticipate that these outstanding questions of islet physi-
ology, including the puzzle of islet GABA function, will
be resolved with the aid of the many biophysical and
genetic tools now available, in particular the biosensor
approach to detecting GABA release.
We thank Dr. P. Maechler and Dr. S. Theander for critical read-
ing of the manuscript.
Olaf S. Andersen served as editor.
Figure 1. Schematic diagram illustrating regulated GABA re-
lease from islet  -cell SLMVs, and the putative pathways by which it
inhibits LDCV secretion in  - and  -cells. Calcium inﬂux through
voltage-dependent calcium channels (VDCC) stimulates GABA
release. Secreted GABA interacts with metabotropic receptors
(GABAB) and ionotropic receptors (GABAA) on recipient  - and
 -cells, respectively. Receptor activation inhibits calcium entry
through VDCCs, in the case of GABAA by hyperpolarizing the
plasma membrane. Reduced calcium inﬂux attenuates LDCV re-
lease in both cell types. The depicted  -cell could also represent a
 -cell, in which case somatostatin would be secreted from LDCVs
in place of glucagon and glutamate. Insulin, zinc, and other prod-
ucts released from  -cell LDCVs probably also act as paracrine in-
hibitors of  -cell glucagon release.190 GABA in the Endocrine Pancreas
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